Cite
HARVARD Citation
Yang, X. et al. (2022). Patient‐reported outcomes of a phase II neoadjuvant apalutamide (ARN‐509) and radical prostatectomy in treatment of intermediate‐ to high‐risk prostate cancer (NEAR) trial. International journal of urology. pp. 1322-1330. [Online].